Kwality Pharma

Why is Kwality Pharmaceuticals Ltd falling/rising?

As of 08-Aug, Kwality Pharmaceuticals Ltd's stock price is at 2,609.05, down 1.64% today despite strong long-term gains. Increased investor participation suggests some are buying at lower prices, but overall market sentiment remains negative, contributing to the stock's decline.

As of 08-Aug, Kwality Pharmaceuticals Ltd's stock price is falling, currently at 2,609.05, reflecting a decrease of 43.4 points or 1.64%. Despite the stock's strong performance over the longer term, with a year-to-date increase of 135.40% and a remarkable 601.26% rise over the past three years, today's trading indicates a downturn. <BR><BR>The stock underperformed its sector by 3.6% today, with an intraday high of Rs 2,710 and a low of Rs 2,490.2, which represents a significant drop of 6.12% from the day's high. The weighted average price suggests that more volume was traded closer to the low price, indicating selling pressure. Additionally, while the stock is above its 50-day, 100-day, and 200-day moving averages, it is below its 5-day and 20-day moving averages, further suggesting a short-term decline in momentum.<BR><BR>Investor participation has increased, with a notable rise in delivery volume by 147.69% against the 5-day average, which could indicate that some investors are taking advantage of the lower price levels. However, the overall market sentiment today appears to be negative, contributing to the stock's decline.

Which are the latest news on Kwality Pharma?

When is the next results date for Kwality Pharmaceuticals Ltd?

The next results date for Kwality Pharmaceuticals Ltd is 10 August 2026.

The next results date for Kwality Pharmaceuticals Ltd is scheduled for 10 August 2026.

Should I buy, sell or hold Kwality Pharmaceuticals Ltd?

What does Kwality Pharma do?

Kwality Pharmaceuticals Ltd is a micro-cap company in the Pharmaceuticals & Biotechnology industry, specializing in manufacturing finished pharmaceuticals, with a market cap of INR 2,581 Cr and reported net sales of 157 Cr and net profit of 25 Cr for March 2026. The company was incorporated in 1983 and has a P/E ratio of 38.00.

Overview: <BR>Kwality Pharmaceuticals Ltd is a micro-cap company operating in the Pharmaceuticals & Biotechnology industry, specializing in the manufacturing of finished pharmaceuticals.<BR><BR>History: <BR>The company was incorporated on May 4th, 1983. It received its first drug license in 1981 for liquid oral manufacturing. The latest quarterly results reported net sales and profit for March 2026.<BR><BR>Financial Snapshot: <BR>Net Sales: 157 Cr (Quarterly Results - Mar 2026) <BR>Net Profit: 25 Cr (Quarterly Results - Mar 2026) <BR>Market Cap: INR 2,581 Cr (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: 38.00 <BR>Industry P/E: 34 <BR>Dividend Yield: 0.00% <BR>Debt-Equity: 0.38 <BR>Return on Equity: 20.49% <BR>Price to Book: 7.32 <BR><BR>Contact Details: <BR>Address: Village Nagkalan, Majitha Road Amritsar Punjab : 143601 <BR>Tel: 91-183-2774321-25 <BR>Email: cs@kwalitypharma.com <BR>Website: http://www.kwalitypharma.com

How big is Kwality Pharma?

As of 10th June, Kwality Pharmaceuticals Ltd has a market capitalization of 2,581.00 Cr, with recent net sales of 503.08 Cr and a net profit of 67.36 Cr. Shareholder's funds are valued at 264.05 Cr, and total assets amount to 445.66 Cr.

As of 10th June, Kwality Pharmaceuticals Ltd has a market capitalization of 2,581.00 Cr, categorized as a Micro Cap.<BR><BR>In the latest four quarters, the company reported Net Sales of 503.08 Cr and a Net Profit of 67.36 Cr.<BR><BR>For the latest annual period, the Shareholder's Funds were valued at 264.05 Cr, and the Total Assets amounted to 445.66 Cr.

Who are in the management team of Kwality Pharma?

The management team of Kwality Pharma includes Ramesh Arora (Managing Director), Ajay Arora, Geeta Arora, Anju Arora, Aditya Arora (CFO), and several independent directors, along with Gurpreet Kaur as Company Secretary. This diverse team oversees the company's operations and governance.

The management team of Kwality Pharma includes the following members:<BR><BR>1. Ramesh Arora - Managing Director<BR>2. Ajay Arora - Whole-time Director<BR>3. Geeta Arora - Whole-time Director<BR>4. Anju Arora - Whole-time Director<BR>5. Aditya Arora - Whole Time Director & CFO<BR>6. Ravi Shanker Singh - Independent Director<BR>7. Pankaj Takkar - Independent Director<BR>8. Kiran Kumar Verma - Independent Director<BR>9. Kartik Kapur - Independent Director<BR>10. Sachin Seth - Director<BR>11. Gurpreet Kaur - Company Secretary & Compliance Officer<BR><BR>This team brings a diverse range of expertise to the company, contributing to its operations and governance.

Who are the peers of the Kwality Pharma?

Kwality Pharma's peers include Unichem Labs, Solara Active, Dishman Carbogen, Morepen Labs, Venus Remedies, Hikal, Indoco Remedies, NGL Fine Chem, and Sakar Healthcare. In terms of management risk, growth, and capital structure, Kwality Pharma is rated average, with a 1-year return of 153.96%.

Peers: The peers of Kwality Pharma are Unichem Labs., Solara Active, Dishman Carbogen, Morepen Labs., Venus Remedies, Hikal, Indoco Remedies, NGL Fine Chem, and Sakar Healthcare.<BR><BR>Quality Snapshot: Excellent management risk is observed at Venus Remedies, while Average management risk is found at Unichem Labs., Morepen Labs., Kwality Pharma, Hikal, Indoco Remedies, NGL Fine Chem, and Sakar Healthcare, and the rest. Below Average management risk is noted for Solara Active and Dishman Carbogen. Growth is rated as Good for Unichem Labs., Venus Remedies, and Dishman Carbogen, while Average growth is seen at Sakar Healthcare, and the rest. Below Average growth is present at Solara Active, Morepen Labs., Hikal, Indoco Remedies, and Kwality Pharma. Capital Structure is Excellent for Morepen Labs., Kwality Pharma, Venus Remedies, and NGL Fine Chem, while Good capital structure is noted at Unichem Labs., and Average capital structure is found at Sakar Healthcare, and the rest. Below Average capital structure is observed at Solara Active, Dishman Carbogen, Hikal, and Indoco Remedies.<BR><BR>Return Snapshot: Venus Remedies has the highest 1-year return at 269.10%, while Dishman Carbogen has the lowest at -38.27%. Kwality Pharma's 1-year return of 153.96% is significantly higher than Dishman Carbogen's. Additionally, Hikal, Indoco Remedies, and Sakar Healthcare have negative six-month returns.

Are Kwality Pharmaceuticals Ltd latest results good or bad?

Kwality Pharmaceuticals Ltd's latest Q4 FY26 results are very good, with a net profit of ₹25.30 crore, up 74.60% year-on-year, and revenue growth of 35.81%. The stock price surged nearly 9% post-announcement, indicating strong investor confidence.

Kwality Pharmaceuticals Ltd's latest results for Q4 FY26 are quite impressive, indicating strong performance. The company reported a net profit of ₹25.30 crore, which reflects a remarkable year-on-year growth of 74.60% and a quarter-on-quarter increase of 58.03%. Revenue also saw significant growth, reaching ₹157.11 crore, up 35.81% year-on-year and 27.28% sequentially.<BR><BR>Furthermore, the operating margin improved to 24.66%, marking the highest quarterly margin recorded, and the profit after tax (PAT) margin expanded to 16.11%, up 360 basis points from the previous year. This demonstrates not only robust revenue growth but also enhanced operational efficiency.<BR><BR>The stock market reacted positively to these results, with the share price surging nearly 9% shortly after the announcement, reflecting growing investor confidence in the company's trajectory. Overall, these results can be characterized as very good, showcasing strong financial health and operational excellence.

Is Kwality Pharma technically bullish or bearish?

As of December 3, 2025, Kwality Pharma's technical trend is bearish with moderate strength, driven by bearish MACD and moving averages, despite a mildly bullish indication from Bollinger Bands on the monthly timeframe.

As of 3 December 2025, the technical trend has changed from mildly bearish to bearish. The current technical stance for Kwality Pharma is bearish with a moderate strength. Key indicators driving this stance include a bearish MACD on the weekly timeframe, bearish moving averages on the daily timeframe, and a bearish KST on the weekly. The Bollinger Bands indicate a mildly bullish trend on the monthly, but overall, the prevailing bearish signals dominate the analysis.

How has been the historical performance of Kwality Pharma?

Kwality Pharma's historical performance shows fluctuating trends, with net sales increasing from 251.03 Cr in Mar'23 to 370.20 Cr in Mar'25, despite a peak of 456.19 Cr in Mar'22. While operating profit and net income improved, the volatility in sales and profit margins indicates a need for strategic stability.

Answer:<BR>The historical performance of Kwality Pharma shows a fluctuating trend in its financial metrics over the years, with notable changes in revenue and profitability.<BR><BR>Breakdown:<BR>Kwality Pharma's net sales increased from 251.03 Cr in Mar'23 to 370.20 Cr in Mar'25, reflecting a significant growth trajectory. However, this growth follows a peak in Mar'22 at 456.19 Cr, indicating volatility in sales performance. Total operating income mirrored this trend, rising to 370.20 Cr in Mar'25 from 251.03 Cr in Mar'23, while total expenditure also increased to 289.81 Cr in Mar'25 from 190.89 Cr in Mar'23. Operating profit, excluding other income, improved to 80.39 Cr in Mar'25, up from 60.14 Cr in Mar'23, although it was significantly higher at 171.67 Cr in Mar'22. Profit before tax also saw an increase to 54.14 Cr in Mar'25 from 25.57 Cr in Mar'23, while profit after tax rose to 39.80 Cr in Mar'25 from 19.28 Cr in Mar'23. The company's total assets grew to 445.66 Cr in Mar'25 from 353.63 Cr in Mar'23, alongside total liabilities which increased to 445.66 Cr from 394.18 Cr in the same period. Cash flow from operating activities improved to 52.00 Cr in Mar'25 from 41.00 Cr in Mar'23, contributing to a net cash inflow of 9.00 Cr in Mar'25, compared to an outflow of 6.00 Cr in Mar'23. Overall, while Kwality Pharma has shown growth in several key areas, the fluctuations in sales and profit margins suggest a need for strategic stability moving forward.

Is Kwality Pharma overvalued or undervalued?

As of November 14, 2025, Kwality Pharma is considered undervalued with a favorable valuation grade, reflected in its PE ratio of 20.24 and strong recent stock performance, especially compared to more expensive peers like Sun Pharma and Divi's Lab.

As of 14 November 2025, the valuation grade for Kwality Pharma has moved from fair to attractive, indicating a positive shift in its market perception. The company is currently considered undervalued based on its key financial ratios, including a PE ratio of 20.24, an EV to EBITDA of 11.51, and a PEG ratio of 0.45, which suggests strong growth potential relative to its price. <BR><BR>In comparison to its peers, Kwality Pharma's valuation appears favorable; for instance, Sun Pharma has a PE ratio of 36.49, while Divi's Lab shows a significantly higher PE of 69.65, both categorizing them as expensive. Additionally, Cipla, which is also rated attractive, has a PE ratio of 22.72, further highlighting Kwality Pharma's relative value. The company's recent stock performance has outpaced the Sensex, with a 1-week return of 11.37% compared to the Sensex's 1.62%, reinforcing the argument for its undervaluation.

Who are the top shareholders of the Kwality Pharma?

The top shareholders of Kwality Pharma are Ramesh Arora, holding 26.01%, and Deepak Bansal, with 10.63%. Individual investors collectively own 33.39%, while there are no mutual funds or foreign institutional investors involved.

The top shareholders of Kwality Pharma include Ramesh Arora, who is the promoter with the highest holding at 26.01%. The highest public shareholder is Deepak Bansal, holding 10.63%. Additionally, individual investors collectively hold 33.39% of the company's shares. There are currently no mutual funds or foreign institutional investors (FIIs) holding shares in the company.

What is the bonus history of the Kwality Pharma?

Kwality Pharma announced a 1:1 bonus issue on October 11, 2017, with a record date of October 12, 2017, allowing shareholders to receive one additional share for each share held.

Kwality Pharma has a bonus history that includes a significant event where the company announced a 1:1 bonus issue. This bonus was declared with an ex-date of October 11, 2017, and the record date was October 12, 2017. This means that shareholders on record as of the record date were entitled to receive one additional share for every share they held.

Has Kwality Pharma declared dividend?

Kwality Pharmaceuticals Ltd has declared a 6% dividend, amounting to 0.6 per share, with an ex-date of January 5, 2017. Despite this, the dividend yield is 0%, as the company has shown substantial price returns over various periods without ongoing dividend payments.

Kwality Pharmaceuticals Ltd has declared a 6% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 6%<BR>- Amount per share: 0.6<BR>- Ex-date: 05 Jan 17<BR><BR>Dividend Yield: 0%<BR><BR>Total Returns by Period:<BR>In the 6 months period, the price return was 5.03%, the dividend return was 0%, resulting in a total return of 5.03%.<BR><BR>For the 1 year period, the price return was 73.5%, the dividend return was 0%, leading to a total return of 73.5%.<BR><BR>Over the 2 years period, the price return was 214.76%, the dividend return was 0%, which culminated in a total return of 214.76%.<BR><BR>In the 3 years period, the price return was 148.67%, the dividend return was 0%, resulting in a total return of 148.67%.<BR><BR>For the 4 years period, the price return was 794.74%, the dividend return was 0%, leading to a total return of 794.74%.<BR><BR>In the 5 years period, the price return was 2571.43%, the dividend return was 0%, culminating in a total return of 2571.43%.<BR><BR>Overall, while Kwality Pharmaceuticals Ltd declared a dividend, the dividend yield remains at 0%. The company has shown significant price returns over various periods, indicating strong growth despite the lack of ongoing dividend payments.